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Viral protein U (Vpu) is an 81 amino acid phosphoprotein found in human immunodeficiency virus type 1 (HIV-1)-infected
cells. One function of Vpu is to enhance the release of virus particles from the plasma membrane in infected cells. Using
subcellular fractionation, we observed that Vpu promotes the targeting of Pr55 Gag to the plasma membrane, the site of viral
assembly. Deletions of Pr55, which removed most of the N-terminal matrix domain (p39) or the C-terminal domains of
nucleocapsid and p6 (p41), still allowed for virus-like particle production. Moreover, the release of these particles remained
Vpu-responsive. The N-terminal matrix (MA) domain of Gag, which contains its membrane-binding domain, is sufficient for
Vpu-mediated enhanced release into the supernatant. Furthermore, a MA-GFP fusion protein showed enhanced membrane
binding in the presence of Vpu. This demonstrates that Vpu action may be mediated by allowing Gag, specifically the
N-terminal matrix domain, to efficiently associate with the plasma membrane. Thus MA appears sufficient but not necessary
for Vpu-mediated enhanced particle release. © 2000 Academic PressKey Words: Vpu; HIV-1 Gag; membrane; matrix.
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The viral Gag protein (Pr55) of human immunodefi-
ciency virus type 1 (HIV-1) is sufficient for virus assembly.
Assembly involves targeting Gag proteins to the plasma
membrane, which is dependent on an N-terminal mem-
brane-binding domain that includes a myristylation sig-
nal and a basic domain. The Gag proteins interact with
each other and bud from the cell surface as immature
virus particles (Garnier et al., 1998; Zhang et al., 1998).
Upon budding the viral protease cleaves the Gag pre-
cursors, producing an infectious, mature virus particle.
Viral protein U (Vpu) is a 17-kDa phosphoprotein
unique to HIV-1 and SIVcpz. infected cells (Cohen et al.,
1988; Strebel et al., 1988; Emerman and Malim, 1998). It
has three known functions. First, it degrades newly syn-
thesized CD4 through the ubiquitin-mediated pathway in
the endoplasmic reticulum (Chen et al., 1993; Lenburg
and Landau, 1993; Raja et al., 1994; Bour et al., 1995; Yao
et al., 1995; Chen et al., 1996; Margottin et al., 1996, 1998;
Schubert et al., 1998). Second, it downregulates expres-
ion of MHC I molecules (Kerkau et al., 1997). Third, Vpu
nhances release of virus particles from infected cells
Gottlinger et al., 1993; Schubert and Strebel, 1994; Jab-
ar, 1995; Schubert et al., 1995; Kobinger et al., 1997). The
1 To whom correspondence and reprint requests should be ad-
ressed at Washington University, Department of Medicine, Division of
olecular Oncology, Box 8069, 660 South Euclid, St. Louis, MO 63110.Pax: (314) 747-2797. E-mail: lratner@imgate.wustl.edu.
305echanism by which Vpu influences virus assembly and
elease is largely unknown. The N-terminal portion of
pu, which includes its transmembrane domain and its
ssociated ion-channel activity, is the critical domain for
nhanced particle release (Ewart et al., 1996; Schubert et
l., 1996a,b; Coady et al., 1998; Moore et al., 1998). The
ag protein is sufficient for Vpu’s enhanced particle
elease phenotype. The p6 domain of Gag, which allows
or efficient budding at the cell surface, is not required for
pu’s effect (Schwartz et al., 1996). Another study showed
hat the N-terminal matrix (MA) domain is important for
he enhanced release of viral particles (Lee et al., 1997).
This study examines the role of Vpu in the release of
irus particles. We have used a vaccinia expression system
hat allows the examination of particle release in the pres-
nce or absence of Vpu expressed in trans. This system
as allowed us to examine a panel of Gag deletion mutants
o define a domain of Gag that is Vpu responsive. Addition-
lly, the subcellular location of Gag proteins in the presence
nd absence of Vpu has also been studied with the use of
ubcellular fractionation techniques and by confocal mi-
roscopy with GAG-GFP fusion proteins.
RESULTS
pu enhancement of the release of virus-like particles
rom 293T cells in a vaccinia expression system
This study examined Vpu’s ability to enhance particle
elease in a T7 driven vaccinia virus expression system.
revious studies have shown the efficient release of
0042-6822/00 $35.00
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306 DEORA, SPEARMAN, AND RATNERauthentic virus-like particles from African green monkey
kidney (BSC-40) cells expressing full-length Gag-Pol
(GPG1) in the vaccinia expression system (Spearman et
l., 1994). The vaccinia system was employed to express
PG1 in 293T cells in the presence or absence of Vpu
pTM-Vpu), also expressed from the T7 promoter in 293T.
igure 1A shows the levels of Gag protein produced in
hese cells. The Gag products immunoprecipitated with
he HIV-1 patient sera include the Gag precursor (p55), a
rocessing intermediate (p41), and capsid (p24). Consis-
ent with experiments performed by other groups that
sed different expression systems, the amounts of Gag
n the lysates of cells expressing Gag alone or Gag plus
pu were similar, or in some cases slightly reduced, in
ysates of cells expressing Gag plus Vpu (Geraghty and
anganiban, 1993; Schubert et al., 1996a; Kobinger et al.,
997; Lee et al., 1997). This varied to some degree over
he course of numerous experiments, as expected with a
ransient expression system. Therefore, Vpu appears to
ave no effect on Gag protein production, since levels of
ell-associated Gag remained fairly constant.
In the supernatants, Vpu expression resulted in en-
anced release of particles in this system. Densitometric
easurements revealed over a 10-fold increase of Gag
roteins released into the supernatant, after normaliza-
ion of total protein levels. Thus Vpu is necessary for
fficient particle release in 293T and HeLa cells (data not
hown), in contrast to African green monkey kidney
BSC-40) cells, which release particles efficiently without
pu coexpression.
We next sought to confirm Vpu-enhanced Gag protein
elease from cells in the form of virus-like particles.
irus-like particles in culture supernatants were pelleted
hrough 20% sucrose and then spun to equilibrium in a
0–60% continuous sucrose gradient. Figure 1B shows
hat in the presence of Vpu, 10-fold more Gag protein
ith a density of 1.16 g/mL was released into the me-
ium. There was no significant difference in particle
ensity detected in the presence versus the absence of
pu in multiple replicates of this experiment. Therefore,
pu allows for the enhanced release of authentic virus-
ike particles.
Varying the amounts of Gag transfected did not alter
pu’s effect. Increasing quantities of GPG1 DNA trans-
ected into cells resulted in more protein in the cell
ysates, as seen in Fig. 1C. However, an increase of
ntracellular Gag protein did not result in an enhance-
ent in the proportion of Gag released into the super-
atant if total protein content was normalized. The effect
f increasing Gag synthesis was the same in the pres-
nce or absence of Vpu (data not shown). Enhanced
ynthesis of Gag, therefore, does not account for the
ffects of Vpu on release of virus-like particles.
Figure 1D examines the effects of Vpu by pulse-chase
nalysis, for which purpose 293T cells were transfected
ith GPG1 alone or GPG1 plus pTM-Vpu. The cells wereabeled for 10 min and incubated in the absence of esotope for periods of 0, 0.5, 1, 2, 5, and 10 h. Similar
mounts of Gag protein were found in the lysates of cells
xpressing Gag alone or Gag plus Vpu (Fig. 1D, top). This
nalysis confirmed that the rate of synthesis of Gag
rotein was not affected by Vpu. In the culture superna-
ant, Gag protein was detected at significantly greater
evels at each time point from cultures expressing Gag
lus Vpu compared to those expressing Gag alone. Thus,
pu has a posttranslational effect to allow for efficient
elease of virus-like particles composed of Gag. More-
ver, Vpu had no effect on the stability of intracellular or
FIG. 1. Enhancement of particle release from 293T cells expressing
Gag with Vpu. 293T cells infected-transfected with pTM3 (parental
vector control), GPG1, or GPG1 plus pTM-Vpu were labeled overnight
with Trans35S Label. (A) Cell lysates and clarified supernatants were
mmunoprecipitated with HIV-1 infected patient antisera and analyzed
y 12% SDS–PAGE. Positions of Gag and Vpu proteins are indicated on
he right, with molecular weight markers shown on the left. (B) Culture
upernatants were analyzed by sucrose density analysis. The amount
f Gag protein in each fraction along with the density of each fraction
s shown. p24 on the left Y-axis reflects densitometric units from an
rbitrary scale of the p24/CA band. (C) Overexpression of Gag does not
ccount for the effects of Vpu on particle release. GPG1 DNA (0, 1, 2, 5,
0 mg) was transfected with 2 mg of pTM-Vpu DNA; cell lysates (top)
and culture supernatants (middle) were analyzed by immunoprecipita-
tion. The proportion of Gag protein released as virus-like particles was
determined after normalization for total Gag protein synthesis (bottom).
(D) Pulse-chase analysis of GPG1 or GPG1 1 Vpu. 293T cells were
pulsed with Trans35S Label for 10 min and chased in the absence of
isotope for 0, 0.5, 1, 2, 5, and 10 h. The top panel shows levels in the cell
lysates; the bottom panel shows viral protein released into the culture
supernatant.xtracellular Gag protein. These findings are consistent
—Conti
L
f
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307Vpu ENHANCED HIV-1 PARTICLE RELEASEwith previously published pulse-chase studies using dif-
ferent expression systems (Jabbar, 1995; Schubert et al.,
1995).
Vpu-enhanced release of Gag deletion mutants
To identify the domains of Gag required for Vpu effects,
deletion constructs in the presence or absence of Vpu
were analyzed. These constructs included 55G1, which
lacks protease and other pol-encoded proteins; 41G1,
which lacks the C-terminal portion of NC and p6; and
39G1, which lacks the matrix domain after the first 14aa
but retains the myristylation signal. While larger dele-
tions or a myristylation minus mutant lost the ability to
produce virus-like particles in this system with or without
Vpu, the mutants studied here retained the capacity to
produce virus-like particles, although most constructs
showed lower levels of virus-like particle release than
full-length GPG1. When the culture supernatants were
analyzed as before in the presence or absence of Vpu, a
5- to 10-fold enhancement of virus-like particle release
was seen when Vpu was coexpressed with Gag (Fig. 2).
Therefore, Vpu appears necessary for efficient particle
release in 293T cells of these deletion mutants. More-
over, these mutants, still capable of forming extracellular
FIG. 1particles, remained Vpu-responsive. sTo control for potential toxicity of the Vpu protein, its
effect on the release of a heterologous protein, human
a-1-antitrypsin (hAAT) was examined. hAAT was ex-
nued
FIG. 2. N- and C-terminal domains of the Gag precursor protein are not
required for Vpu-enhanced particle release. Gag deletion mutants were
expressed in 293T cells with or without Vpu. After labeling with Trans35S
abel and immunoprecipitation, SDS–PAGE and densitometry were per-
ormed. The top panel shows cell lysates expressing pTM3, 55G1, 41G1,
nd 39G1, each with or without coexpression of Vpu. The bottom panel
hows the results from culture supernatants of these transfections.
r
s
a
i
d
308 DEORA, SPEARMAN, AND RATNERpressed in 293T cells that were infected-transfected with
pTM-Vpu. Cells and culture supernatants were treated
with lysis buffer and analyzed for levels of hAAT protein
by ELISA. In the presence or absence of Vpu, equivalent
levels of hAAT were secreted (data not shown). This lack
of effect on hAAT secretion shows that Vpu does not alter
the secretory pathway, nor is Vpu functioning by inducing
FIG. 3. Gag protein localization in fractionated cells shows a shift
from cytoplasmic to plasma membrane fractions with the coexpression
of Vpu. 293T cells expressing GPG1 alone, or GPG1 with Vpu, were
labeled and then fractionated using Percoll self-forming gradients. (A)
Marker enzyme assays were used to determine which fractions contain
particular cellular compartments. Lactate dehydrogenase was used as
a cytoplasmic marker and its activity was found in the first two frac-
tions. Alkaline phosphodiesterase was used as a plasma membrane
marker and its activity was associated with fractions 4 and 5. (B) The
same fractions were immunoprecipitated with HIV-1 infected patient
antisera and analyzed by 12.5% SDS–PAGE and densitometry. The
amount of Gag protein seen in each fraction is graphed.cell death or enhancing cell permeability to proteins.Subcellular fractionation by Percoll gradients for Gag
localization in the presence or absence of Vpu
Because HIV-1, like type C retroviruses, requires as-
sembly to occur at the plasma membrane, the intracel-
lular distribution of Gag was examined by subcellular
fractionation (Morand and Kent, 1986). Figure 3A shows
that after fractionation of the cell on a 15% Percoll gra-
dient, the cytosolic components remained in the top two
fractions of the gradient, as indicated by lactate dehy-
drogenase activity measurements. The plasma mem-
brane marker alkaline phosphodiesterase was found in
fractions 4 and 5 of the gradient. All fractions of the
gradient were then immunoprecipitated with HIV-in-
fected patient antisera, run on a 12% SDS–PAGE gel, and
analyzed by densitometry. Figure 3B shows that the ma-
jority of Gag protein is present in the top cytosolic frac-
tions when Gag is expressed alone. However, in the
presence of Vpu, there is a shift of Gag protein to the
more dense membrane-containing fractions 4 and 5.
Vpu-mediated enhanced release of a pelletable MA
Because the membrane-binding motif in Gag is
thought to be in the N-terminal matrix (MA) domain
(Verderame et al., 1996; Zhou and Resh, 1996), this
egion was further analyzed in the vaccinia expression
ystem. Previous work has shown that MA of both SIV
nd HIV-1 is capable of being released into the media
n a pelletable form (Gonzalez et al., 1993, 1996; Gid-
ings et al., 1998; Wang et al., 1999). The nature of
pelletable MA in HIV-1 is controversial. Wang et al.
(1999) have shown MA banding in a sucrose gradient
with a density of 1.12 g/mL, and it can also be visual-
FIG. 4. Vpu enhances the release of the MA domain of Gag. pTM-MA,
which expresses just the MA domain of Gag, was expressed in the
presence and absence of Vpu. (A) 293T cell lysates were analyzed by
Western blot by the use of HIV-1 infected patient antisera to examine
MA and Vpu expression, as indicated. (B) Culture supernatants were
pelleted through a 4-mL 20% sucrose cushion, and the resuspended
pellet was analyzed by Western blot with a monoclonal MA antibody.
MM
309Vpu ENHANCED HIV-1 PARTICLE RELEASEized by electron microscopy. Therefore, MA cloned
into pTM3, pTM-MA, was expressed in 293T cells with
or without pTM-Vpu. The cells were lysed directly. The
supernatants were layered over a 4-mL 20% sucrose
cushion and virus-like particles were pelleted. The
pellet was resuspended in 1 mL of RIPA buffer, and
Gag protein in the cell lysate and the supernatant
were analyzed by SDS–PAGE and Western blot. Figure
4A shows the cell lysates probed with HIV-1 infected
patient antisera to detect both MA and Vpu proteins.
Equivalent levels of matrix protein were synthesized in
the presence or absence of Vpu. Figure 4B shows the
pelleted supernatants. The pelleted MA was probed
with a more sensitive, anti-MA monoclonal antibody,
which was required for detection of this pelleted pro-
tein. In this case, a 20-fold enhancement in the release
of pelletable MA is seen in 293T cells expressing Vpu
versus cells expressing MA alone.
Localization of a MA-GFP fusion construct
in the presence or absence of Vpu
Localization of pTM-MA expressed in the presence and
absence of Vpu was also examined. In this case, a MA-GFP
fusion protein was used (Sandefur et al., 1998). This con-
struct fuses the green fluorescent protein (GFP) onto the
FIG. 5. Effect of Vpu on MA-GFP localization. A MA-GFP fusion prote
in 4% paraformaldehyde and analyzed with a Zeiss axiovert microscop
633). The top panels showing MA alone show characteristic pattern o
distinct plasma membrane staining in the first and third panels, whi
membrane staining.C-terminus of the MA protein. This fusion protein wascloned into the pTM3 vector and expressed in 293T cells
using the vaccinia infection-transfection protocol. As previ-
ously reported for MA-GFP in BSC-40 cells, the majority of
MA-GFP is distributed throughout the cell in a cytoplasmic
distribution (Spearman et al., 1997). Interestingly, when MA-
GFP was expressed in the presence of Vpu, the fluores-
cence is shifted to a plasma membrane pattern in a signif-
icant proportion of cells. Figure 5 shows examples of fluo-
rescence patterns in cells expressing MA-GFP alone
versus cells expressing MA-GFP plus Vpu. Table 1 is a
quantitative analysis of the number of cells which express
TABLE 1
Quantification of Cells Expressing MA-GFP
at the Plasma Membrane 6 Vpu
Cells expressing
Fluorescent
cells
Cells with
PM staining
Cells at PM
(%)
A-GFP
Experiment 1 25 1 4
Experiment 2 35 4 11
Total 60 5 8.3
A-GFP 1 Vpu
Experiment 1 25 10 40
Experiment 2 27 12 44
Total 52 22 42
expressed in the presence or absence of Vpu. 293T cells were fixed
ped with a BioRad confocal scanning imaging system (magnification,
e cytoplasmic staining. The bottom panels of MA-GFP plus Vpu show
iddle panel shows cells with some cytoplasmic and some plasmain was
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310 DEORA, SPEARMAN, AND RATNERMA-GFP protein at the plasma membrane. Eight percent of
cells expressing MA alone have plasma membrane stain-
ing, whereas 92% of the cells show a diffuse cytoplasmic
distribution of MA-GFP (Fig. 5, panels 1–3). However, 42% of
cells expressing MA and Vpu exhibit plasma membrane
staining (Fig. 5, panels 4 and 6), with 58% of cells showing
a more diffuse cytoplasmic distribution of MA-GFP (Fig. 5,
panel 5).
DISCUSSION
These results indicate that Vpu may be acting at the
plasma membrane targeting event in HIV-1 particle as-
sembly. Targeting of Gag to the plasma membrane is an
essential step in viral assembly. It also appears that Vpu
acts on the MA domain of Gag, which contains a bipartite
membrane binding signal of myristylation and a basic
domain (Zhou and Resh, 1996). MA is sufficient for Vpu’s
effect on particle release. This is consistent with other
studies which report that MA is necessary for Vpu’s
effect on particle enhancement (Lee et al., 1997). How-
ever, our data show that, after its initial N-terminal myri-
stylation signal, MA is sufficient but not necessary for
enhanced particle release. Gottlinger et al. (1993) have
also shown that Gag proteins from a wide range of
retroviruses, with very different N-terminal MA domains,
are responsive to Vpu. Also, extensive deletions in the
MA domain from the Gag precursor protein do not abro-
gate the effects of Vpu. These deletions include 39G1,
which removes amino acids 14–131, and D8–31 (data not
shown), which removes the basic domain of MA that is
part of the membrane-binding signal. At least three po-
tential explanations exist: (1) Gag has more than one
domain that is Vpu responsive; (2) the Vpu responsive
region lies in the myristylation signal of HIV-1 MA, which
is a motif that cannot be mutated without abrogating
particle assembly; or (3) Vpu is acting by altering the
cellular environment in a way that allows for more effi-
cient membrane binding of Gag.
The first possibility of more than one Vpu-responsive
domain could be analyzed by further deletion mutants.
One possible region includes the N-terminal residues of
NC, which have been shown to be critical for membrane
targeting with Gag-GFP fusion constructs (Sandefur et
al., 1998). If another region is also Vpu responsive, it may
be necessary to remove both domains to abrogate Vpu-
mediated particle enhancement.
The second possibility of the myristylation signal being
the mediator of Vpu’s effect on particle release is also
intriguing. Vpu does not appear to change the level of
myristylation (data not shown). However several groups
have shown that the myristyl group of Gag may be buried
in certain situations and exposed at other times during
the viral life cycle, via a myristyl switch mechanism (Zhou
and Resh, 1996; Spearman et al., 1997). The current
studies using subcellular fractionation and confocal
analysis show that Vpu enhances membrane binding of dGag. These findings, together with the demonstration
that myristylation is important for assembly of HIV-1 at
the plasma membrane, provide a possible mechanism
whereby Vpu may allow for the myristyl group of Gag to
be more exposed and allow for its efficient binding to the
plasma membrane.
Finally, Vpu may be acting indirectly on Gag. Its effect
may be exerted on the cellular environment. BSC-40 and
COS cells have been shown to release particles effi-
ciently without Vpu coexpression. Thus, Vpu appears
necessary in certain cell types for enhanced particle
release. The effects on particle release and membrane
binding seen in these studies may be the result of Vpu
altering the cellular environment. The ion-channel activ-
ity of Vpu maps to the same region of Vpu that is nec-
essary for enhanced particle release (Schubert et al.,
996b). The cellular milieu could affect the membrane to
llow for enhanced Gag binding and release. Alterna-
ively, Vpu could affect Gag structure allosterically, per-
aps triggering the myristyl switch, to allow for enhanced
embrane binding and release.
Further studies will be aimed at determining which of
hese three possibilities is responsible for the effects of
pu on virus assembly and release. This analysis will
elp to elucidate the process whereby Gag proteins,
nitially synthesized in the cytosol, are routed to the
lasma membrane. Determining the role of different do-
ains in Gag, including MA, and other potential mem-
rane binding domains, will be important to further elu-
idate the mechanism of subcellular targeting. The role
f viral accessory proteins and their interaction with Gag
roteins as well as the cellular environment may also
rovide interesting new information on the viral assem-
ly process.
MATERIALS AND METHODS
ell growth and infection-transfection
293T and HeLa cells were maintained in DMEM plus
0% FCS, 1 mM sodium pyruvate, 50mg/mL penicillin,
and 50 U/mL streptomycin. The cells were grown at 37°C
in a 5% CO2 environment. For transfection, cells were first
nfected with a recombinant vaccinia virus expressing T7
olymerase, vTF7–3, at a multiplicity of infection of 10. At
.5 h postinfection, cells were transfected with a total of
0 mg DNA using lipofectamine (GIBCO-BRL). Five hours
posttransfection, the media was removed and either la-
beled with 50 mCi/mL Tran35SLabel (ICN) for immunopre-
ipitation analysis or replaced with DMEM plus 10% FCS
or Western blot analysis.
lasmids
All constructs were cloned into the parental vector
TM3 for expression in the vaccinia expression system.
PG1, 55G1, 41G1, 39G1, and pTM-MA were cloned as
escribed previously (Spearman and Ratner, 1996). MA-
l311Vpu ENHANCED HIV-1 PARTICLE RELEASEGFP was cloned as described previously (Sandefur et al.,
1998). pTM-Vpu was created by amplification of vpu from
HIV-1 ADA by PCR. The fragment was then digested with
NcoI at the 59 end and EcoRI at the 39end. This fragment
was then ligated into pTM3, also cut with NcoI and
EcoRI.
Sucrose cushion and sucrose density gradient
analysis
For confirmation of authentic viral particle production
culture, supernatants were initially layered over 4 mL of
20% sucrose and spun at 4°C in a SW28.1 (Beckman)
rotor for 1.5 h at 25,000 rpm. For pTM-MA, this pellet was
then resuspended in RIPA buffer (1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 0.15 M NaCl, and 50 mM Tris
[pH 8.0]), and analyzed by Western blot. For GPG1, this
viral pellet was resuspended in PBS and layered over a
20–60% continuous sucrose gradient. This gradient was
spun in a SW28.1 rotor for 16 h at 20,000 rpm. The
fractions in the gradient were collected manually from
the top of the gradient. Each fraction was then lysed in
23 RIPA buffer and analyzed by immunoprecipitation.
Pulse-chase analysis
293T cells were infected-transfected for 5 h as de-
scribed earlier. Labeling medium lacking isotope was
then added for 20 min. This was followed by the addition
of labeling medium with 100 mCi/mL of Tran35SLabel for
a 10-min pulse. Media lacking isotope was then added
back, and cells and culture supernatants were harvested
as described earlier at 0, 0.5, 1, 2, 5, and 10 h. These
samples were then analyzed by immunoprecipitation,
SDS–PAGE, and densitometry.
Immunoprecipitation and Western blots
For immunoprecipitations and Western blots, cells and
clarified culture supernatants were initially disrupted in
lysis buffer (50 mM Tris, 0.15 M NaCl, 1 mg/mL PMSF, 1
mg/mL aprotinin, and 1% Triton X-100). The cell lysates
were then centrifuged at 14,000 rpm for 10 min to remove
unbroken cells and nuclei. For immunoprecipitations the
supernatants and postnuclear cell lysates were then
immunoprecipitated with HIV-infected patient antisera.
Immunoprecipitates were loaded on a 12.5% SDS–PAGE
gel and analyzed by fluorography and densitometry (Ul-
troscan XL Enhanced Laser Densitometer). For Western
blots, the culture supernatants were layered over a 4-mL
20% sucrose cushion and then spun at 25K for 1.5 h in a
SW28.1 rotor at 4°C. The pellet was resuspended in 1 mL
of RIPA buffer, and then the cell lysate and the superna-
tant were analyzed on SDS–PAGE and Western blot with
an anti-MA monoclonal antibody or HIV-1 patient anti-
sera.Subcellular fractionation
293T cells were infected-transfected as previously de-
scribed with GPG1 or GPG1 1 pTM-Vpu, followed by
abeling with 100 mCi/mL of Tran35S Label overnight.
Cells were then washed, placed in a hypotonic buffer (0.1
M NaCl, 10 mM Tris [pH 7.5], 1 mM EDTA, PMSF, and
aprotinin), and disrupted by Dounce homogenization.
The cell lysates were then adjusted to 0.15 M NaCl and
DNAse I (250 mg/mg cell protein) was added to prevent
aggregation resulting from the release of the nuclear
DNA. The lysates were then layered over a 15% Percoll
solution made in 0.25 M sucrose and spun at 38K for 30
min to allow the formation of the gradients. Fractions
were then taken from the top of the gradient and ana-
lyzed for enzymatic activities of lactate dehydrogenase
as a cytosolic marker and alkaline phosphodiesterase as
a plasma membrane marker.
GFP analysis
The MA-GFP construct was expressed in 293T cells as
described previously. After an overnight transfection,
cells were fixed in fresh 4% paraformaldehyde for 30 min
at room temperature. Cells were then examined on a
Zeiss axiovert microscope equipped with a BioRad con-
focal scanning imaging system (magnification, 633).
Cells with a diffuse cytoplasmic staining were classified
as having a cytoplasmic distribution of protein, whereas
cells that had a distinct staining along the cell periphery
were classified as having a plasma membrane distribu-
tion. Quantitation was performed on coded panels of
slides in a blinded fashion.
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